FDA Advisory Committee recommends Northera(Chelsea Therapeutics) for Symptomatic Neurogenic Orthostatic Hypotension

The FDA Cardiovascular and Renal Drugs Advisory Committee voted 7-4 with 1 abstention and 1 non-vote to recommend approval of Northera (droxidopa) for the treatment of Symptomatic Neurogenic Orthostatic Hypotension (also known as Neurogenic OH or NOH) in patients with primary autonomic failure (Parkinson's disease, multiple system atrophy and pure autonomic failure), dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy.The FDA will deicde on the application on 28 March 2012